Costello Medical ISPOR Presentations

ISPOR 5th Latin America Conference, September 2015, Santiago, Chile

IP2 Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation?
Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I

PP4 An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs?
Montgomery S, Stewart G, Kusel J

PHP23 Pharmaceutical Cost-Containment Strategies - Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America
Beale R, Stewart G, Agirrezabal I, Kusel J

PHP24 Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines
Burgon J, Bunting C, Eddowes LA, Wilson T

PHP38 Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America
Griffiths M, Latchford J, Stewart G, Kusel J

PHP40 Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease
Anderson R, Wilson T

PHP54 Disinvestment Initiatives in Latin America: A Systematic Literature Review
Agirrezabal I, Latchford J, Gutierrez-Ibarluzea I

PRM9 A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results
Stewart G, Slater D, Maruszczak M

ISPOR 20th Annual International Meeting, May 2015, Philadelphia, USA

PMD34 The A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA
Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Toröök ME

PMD37 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of Clostridium difficile
Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Toröök ME, Sagoo GS

PRM28 Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden
Kusel J, Beale R, Maruszczak M

PHP107 The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time
Griffiths M, Maruszczak M, Kusel J
ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands

**W5 Value-based Assessment for NICE: How to Do the Calculations**
Kusel J, Boysen M, Hatswell AJ, Shah K

**HS3 Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals**
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

**QA1 Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications**
Montgomery S, Hassan M, Kusel J

**NI2 Predicting the Impact of Value-based Assessment on Future NICE Appraisals**
Beale RC, Maruszczak M, Kusel J

**PGI17 A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective**
Miles G, Leonard SA, Ghosh N, Premchand P

**PND49 Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis**
Maruszczak M, Kusel J, Adlard N

**PMH63 Antidepressant Use and Suicide Rate in England: The Geographic Divide**
Anderson R, Wilson T, Griffiths M

**PRM124 Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn’s Disease in Hypertensive Patients**
Maruszczak M, Stewart G, Kusel J, Brown MJ

**PRM28 Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK**
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

**PCN260 Investigating the Use of Personalised Medicine in Cancer Trials - An Update**
Hamilton K, Wilson T

ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China

**IP2 Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?**
Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

**QA2 An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan**
Stewart G, Brooks-Rooney C

**PCN13 Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach**
Agirrezabal I, Bunting C, Brooks-Rooney C

**PCN39 The Differences Between Cancer Drug Approvals in Japan and the USA**
Anderson R, Brooks-Rooney C

**PDB9 Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-diabetes Drugs - Case Study of Liraglutide in Asian and Non-Asian Populations**

**PMS30 Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia**
Hamilton KI, Eddowes LA, Brooks-Rooney C

**PIN33 The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA**
Anderson R, Brooks-Rooney C
HC2 The Impact of NICE's End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales
Stewart G, Eddowes L, Hamerslag L, Kusel J

PHP27 An Update on How NICE Manage Off-Label Comparators
Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

PGI30 Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England
Hamilton K, Kusel J, Leonard S

PDB128 Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?
Marsh W, Wilson T, Kusel J

ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

IP13 Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?
Kusel J, Walker W, Spackman E, Andersson C

PCN207 Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data
Wilson T, Hamerslag L, Kusel J

PHP152 The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval
Burgon J, Hamerslag L

PHP166 How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?
Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68 How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK
Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27 Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs
Miles G, Bell J, Wilson T, Hamerslag L, Kusel J

ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89 Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?
Hay J, Barber R, Kusel J, Wilson T

PMS48 Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104 Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany

NI2 The Use of Off-Label Comparators in NICE Appraisals - An Indirect Endorsement?
Kusel J, Wong GK, Hay JA, Pettit LJ

CA2 Applying a Value-Based Price Across Different Disease Areas
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE’s End-of-Life Therapies?
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L
### ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

**HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?**

**PHP82 The Characteristics of Clinical Trials in Asia**
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

**PRM11 The Use of Biomarkers in Cancer Trials in Asia**
Hamerslag L, Wilson T, Brooks-Rooney C

### ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

**PCN148 The Use of Personalised Medicine in Cancer Trials**

**PHP66 Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance**
Timm B, Leonard S, Haynes S

**PRM11 The Rise of Budget Impact Analyses - Another Hurdle in the Health Technology Approval Process?**
Wong GKW, Hamer N, Wilson T, Costello S

### ISPOR 14th Annual European Congress, November 2011, Madrid, Spain

**RS2 Cost-effectiveness of End-of-life, Life-extending Interventions: NICE’s Cost-effectiveness Threshold Explored**
Hamerslag L, Haynes S, Kusel J, Costello S

**RS4 The Interim Cancer Drugs Fund - How To Not Spend £50 Million**
Timm B, Brooks-Rooney C, Hamerslag L, Costello S

**PHP123 To What Extent Does Advice From the SMC Agree with that Published by NICE?**
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

**PHP145 The Burden of Evidence in the Pharmaceutical Appraisal Process**

**PHP152 The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study**

**PRM9 What Guidance is Available for Budget Impact Analysis?**
Kusel J, Leonard S, Wilson T, Costello S

### ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

**PRM3 The Burden of Caregiving: Assessing the Status of Current Clinical Research**
Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

**PHP5 Incentive-based Interventions - Rewarding Patients for Good Behaviour**
Haynes S, Costello S, Brooks-Rooney C, Hamer N

**PHP7 Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence I dentified by NICE in the UK**
Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

**PHP43 The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK**

**PHP89 The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions**
Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

**PMS69 The Use of Mixed Treatment Comparisons in NICE Technology Appraisals**
ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4 Do Patient Access Schemes Result in an Acceptable Administrative Burden?
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94 Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

PHP98 Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79 Innovative Pricing Agreements in UK NICE Submissions
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N